Browse our wide selection of products for your research needs
We can offer a discount on bulk orders.
Please contact our sales team for further inquiry.
| Product Name | DOX-PD-L1-FD1080@LNP |
| Catalog Number | R-Z-DPF-1 |
| Alias | Doxorubicin-PD-L1-FD1080@LNP |
| Appearance | Dispersion |
| Molecular Formula | N/A |
| Solubility | Dispersed in aqueous medium |
| Storage | -20°C, protected from light |
| Purity | 95%+ |
| Shelf Life | 1 year |
| Shipping Condition | low temperature transport |
| Application | drug research and development |
| Specification | 10mg:Inquiry 20mg:Inquiry 50mg:Inquiry |
| Description | DOX/PD-L1/FD1080@LNP is a multifunctional lipid nanoparticle drug delivery system. As a carrier, lipid nanoparticles (LNP) have good biocompatibility, adjustable particle size and surface properties, and can effectively protect the drug molecules wrapped in them to avoid premature degradation or elimination in the body. Doxorubicin (DOX) exerts harmful effects on cells by intercalating into DNA double strands and interfering with DNA replication and transcription. PD-L1 inhibitors can block the combination of PD-L1 and PD-1, activate the body's immunity system, and enhance the ability of immune cells to clear tumor cells. Although the specific substance of FD1080 is not specified, it may be an auxiliary treatment drug or a molecule with special functions. The three are co-loaded in LNP, which can achieve tumor-targeted delivery and use PD-L1 inhibitors to activate the immunity response, while FD1080 works synergistically. |